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The ubiquitous multisubunit vacuolar-type proton pump (H- or V-ATPase) is essential for acidification of diverse intracel-
lular compartments. It is also present in specialized forms at the plasma membrane of intercalated cells in the distal nephron,
where it is required for urine acidification, and in osteoclasts, playing an important role in bone resorption by acid secretion
across the ruffled border membrane. It was reported previously that, in human, several of the renal pump’s constituent
subunits are encoded by genes that are different from those that are ubiquitously expressed. These paralogous proteins may
be important in differential functions, targeting or regulation of H-ATPases. They include the d subunit, where d1 is
ubiquitous whereas d2 has a limited tissue expression. This article reports on an investigation of d2. It was first confirmed that
in mouse, as in human, kidney and bone are two of the main sites of d2 mRNA expression. d2 mRNA and protein appear later
during nephrogenesis than does the ubiquitously expressed E1 subunit. Mouse nephron-segment reverse transcription–PCR
revealed detectable mRNA in all segments except thin limb of Henle’s loop and distal convoluted tubule. However, with the
use of a novel d2-specific antibody, high-intensity d2 staining was observed only in intercalated cells of the collecting duct
in fresh-frozen human kidney, where it co-localized with the a4 subunit in the characteristic plasma membrane-enhanced
pattern. In human bone, d2 co-localized with the a3 subunit in osteoclasts. This different subunit association in different
tissues emphasizes the possibility of the H-ATPase as a future therapeutic target.
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T he multisubunit vacuolar-type proton pump (H
- or
V-ATPase) is essential for acidification of diverse intra-
cellular compartments in eukaryotic cells, including
endosomes, lysosomes, clathrin-coated and synaptic vesicles,
chromaffin granules, and the central vacuoles of plants and fungi.
In addition, H-ATPases function to pump protons across the
plasma membrane of certain cell types, one such example being
the H-ATPases present at high density at the apical surface of
-intercalated cells in the collecting duct of the distal nephron,
where vectorial proton transport is required for urinary acidifica-
tion and the maintenance of acid-base homeostasis (1).
Plasma membrane H-ATPases also play an important role
in bone resorption by osteoclasts (2). Osteoclasts form a sealed
extracellular compartment (resorption lacuna) between the
plasma membrane (ruffled border) and the bone surface. Large
numbers of H-ATPases present in the ruffled border acidify
this resorption lacuna, facilitating mineral solubilization and
the hydrolysis of bone matrix by proteolytic enzymes such as
cathepsin K (3).
The general structure of H-ATPases comprises two func-
tional sectors, V1 and V0. The peripheral V1 domain binds and
hydrolyzes ATP, providing the energy for H translocation
across the integral membrane V0 domain. The complete identity
of all of the pump components has yet to be elucidated, but the
structural model put forward by Nishi and Forgac (4), based
mostly on studies of the bovine clathrin-coated vesicle and
yeast H-ATPases, suggests that there are at least 13 different
subunits. In this model (Figure 1), the V1 domain (640 kD)
comprises subunits A through H, in a proposed stoichiometry
of A3B3C1D1E1F1G2H1, whereas V0 (260 kD) contains five sub-
units in a possible complex of a1d1c1(c, c)5–6, although
whether the c subunit is present in all species is currently
unclear. Another integral membrane protein, the e subunit, also
referred to as M9.7 or M9.2, was recently shown to be essential
for H-ATPase activity in yeast and is probably a functionally
essential part of all eukaryotic H-ATPases (5).
Received September 13, 2004. Accepted February 15, 2005.
Published online ahead of print. Publication date available at www.jasn.org.
Address correspondence to: Dr. Fiona Karet, Cambridge Institute for Medical
Research, Box 139 Addenbrooke’s Hospital, Cambridge, CB2 2XY, UK. Phone:
44-1223-762617; Fax: 44-1223-331206; E-mail: fek1000@cam.ac.uk
Copyright © 2005 by the American Society of Nephrology ISSN: 1046-6673/1605-1245
The precise function(s) of many of the proton pump’s sub-
units and the interactions between them remain undetermined.
Moreover, in higher eukaryotes, several H-ATPase subunits
have recently been shown to have multiple isoforms encoded
by different genes and with differing tissue expression patterns,
as summarized in Table 1. These include the B, C, E, G, a, d, and
e subunits (6–12). The existence of different subunit isoforms
may play an important role in the localization and activity of
proton pumps in specific cell types and subcellular compart-
ments. In support of this hypothesis, we showed previously
that in human, mutations in the genes encoding B1 and a4,
isoforms of the B and a-subunits that are predominantly ex-
pressed in the apical proton pumps of -intercalated cells in the
kidney, cause autosomal recessive distal renal tubular acidosis
(RTA) (13,14). Similarly, autosomal recessive osteopetrosis
(ARO) can be caused by mutations in a3 (15,16), a different
isoform of the a-subunit that is chiefly expressed in proton
pumps at the ruffled border of osteoclasts. These observations
suggest that the normal functioning of some specialized types
of H-ATPase is dependent on the presence of particular sub-
unit isoforms, which cannot be substituted fully by a different
isoform of the same subunit.
We showed previously that in human, the d2 subunit gene is
expressed predominantly in kidney and osteoclasts, whereas
d1 is ubiquitously expressed (10). We now report an investiga-
tion into the distribution of d2 in kidney and bone. We also
analyzed the expression of the d2 subunit during mouse and
human nephrogenesis and compared this with expression of the
ubiquitously expressed d1 and E1 subunits, as well as with a3.
Materials and Methods
Ethical Approval
All tissues were procured with appropriate institutional ethical ap-
proval (Addenbrooke’s Hospital Local Research Ethics Committee,
Universite´ catholique de Louvain Ethical Review Board).
Reverse Transcription–PCR
Total RNA was prepared from freshly harvested mouse tissues using
TRIzol Reagent (Invitrogen, San Diego, CA) by standard methods. Two
micrograms each of kidney, liver, testis, bone, brain, heart, skeletal
muscle, lung, spleen, and thymus RNA was treated with RQ1 RNase-
free DNase I (Promega, Madison, WI) and then reverse-transcribed
using Super RT (HT Biotechnology Ltd, Cambridge, UK) and oligo
p(dT)18 (New England BioLabs, Beverly, MA) as primer according to
the manufacturer’s protocol. An aliquot of each cDNA preparation was
used as template for PCR with the following primers: Atp6v0d1, AG-
CAGATGGAGGCTGTGAACATC and ACACCAAAATGGAACTG-
GTTCAGG; Atp6v0d2, CAGAGATGGAAGCTGTCAACATTG and
ACACCATAATGGAATTGCCTGTTG. These primers lie in exons 3
and 8 of both Atp6v0d1 and Atp6v0d2, and the expected products are
535 and 532 bp in size, respectively. For confirming successful reverse
transcription, a 540-bp fragment of -actin was amplified in parallel
using the primers GTGGGCCGCCCTAGGCAC and CTCTTTGATGT-
CACGCACGATTTC. In each experiment, sterile water was used as
template to provide a negative control. Reverse transcription reactions
performed in the absence of enzyme provided a negative control sam-
ple for each tissue (data not shown). PCR fragments were resolved by
electrophoresis in a 2% agarose gel.
Nephron Segment Isolation and Reverse Transcription–PCR
C57BL/6J mice (male, 25 to 30 g; Jackson Laboratory, Bar Harbor,
ME) were anesthetized with ketamine and perfused through the left
ventricle with PBS that contained 250 g/ml collagenase (Sigma, St.
Louis, MO). The kidneys were rapidly removed, and coronal slices 2 to
3 mm thick were cut and incubated in PBS/collagenase at 37°C for 15
min. After rinsing with ice-cold PBS, nephron segments were hand-
dissected and placed in TRIzol. Total RNA was extracted and reverse-
transcribed as described above. An aliquot of each cDNA preparation
was amplified by PCR using the Atp6v0d2 primers shown above. A
452-bp fragment of glyceraldehyde-3-phosphate dehydrogenase
(G3PDH) was amplified in parallel using the primers ACCACAGTC-
CATGCCATCAC and TCCACCACCCTGTTGCTGTA. In each experi-
ment, sterile water was used as template to provide a negative control.
Polyclonal Antisera
Two peptides, one containing 13 internal residues of human d2
(amino acids 67 to 79; VSKIDTEMRKRLC, peptide 1) and one corre-
sponding to the C terminal 17 residues (amino acids 334 to 350;
CISQRHRTKINSYIPIL, peptide 2) were synthesized, conjugated to key-
hole limpet hemocyanin, and used to raise a guinea pig polyclonal
antiserum, designated SK20 (Eurogentec, Seraing, Belgium).
Western Blot Analysis
Western blot analysis was carried out by standard methods, using
nonfat dried milk as the blocking agent, and SK20 antiserum, either at
1:1000 dilution or 1:50, after affinity purification against peptide 2.
Preimmune serum from the same animal was used as a control. Extracts
of human renal cortex, rat and mouse whole kidney, and mouse brain
were prepared by grinding up 0.5 to 1.0 g of snap-frozen tissue under
liquid nitrogen, transferring to homogenization buffer (10 mM Tris, 150
mM NaCl, 2 mM PMSF, 1 mM EGTA, 1 mM EDTA, and 1 mM DTT,
Figure 1. Schematic model of the H-ATPase. Adapted from
reference 4. The peripheral V1 domain subunits A through H
are indicated by open symbols, and the integral membrane V0
domain subunits a, c, and c are shown as gray hatched sym-
bols, with the subject of this study, the d subunit, being indi-
cated by darker hatching. The c subunit is not shown because
it may not be present in all H-ATPases, and the e subunit was
not included in this model. *The a-subunit has four different
isoforms; those most relevant to this study are a3 and a4, which
are present in the proton pumps found at the ruffled border of
osteoclasts and the cell surface of renal intercalated cells, re-
spectively.
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Table 1. Mammalian H-ATPase subunits expressed at specialized sites in kidney and bonea
Subunit Tissue Species mRNA Protein
Evidence for Presence in
Specialized H-ATPase References
Technique Site
B1 Kidney Human   IL IC plasma membrane
(co-localizes with a4)
13,14,35




Bovine   6
Rat  IL IC plasma membrane 6
Inner ear Human  13
Mouse  IL Endolymphatic sac/
cochlea
13
Placenta Human  35
Male genital
tract
Mouse   IL Epididymis 29
Rat  IL Epididymis/vas
deferens
36
Eye Rat  IL Ciliary epithelium 37
Rabbit  IL Ciliary epithelium 37
C2 Kidney Human  10
Mouse (C2b)   IL IC plasma membrane 11,26
Co-IP (B1) Kidney membranes 26
Placenta Human  10
Lung Mouse (C2a)   IL Type II alveolar cells 11,26
G3 Kidney Human  10
Mouse   IL IC plasma membrane 11,26
Co-IP (B1) Kidney membranes 26
a3b Bone Human   IL Osteoclasts (co-localizes
with d2c)
15,24,38
Mouse   IL Osteoclasts 22,25,39,40
Rabbit  ISH Osteoclasts 41




Mouse   IL IC plasma membrane 7,8,21,26
Co-IP (B1, B2) Kidney membranes 26
Inner ear Human  42
Mouse  IL Endolymphatic sac 43
Male genital
tract
Mouse  IL Epididymis/vas
deferens
8,21
d2b Kidney Human   IL IC plasma membrane
(co-localizes with a4c)
10
Mouse  c  IL IC plasma membrane 11,26,33
Co-IP (B1) Kidney membranes 26




Lung Human  10
Mouse  c 33
aCo-IP, co-immunoprecipitation; IL, immunolocalization; ISH, in situ hybridization; IC, intercalated cells.
bmRNA has been observed at low levels in more widespread distribution.
cThis study.
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with one Complete Mini EDTA-free Protease Inhibitor Cocktail tablet
[Roche, Lewes, UK] per 10 ml of buffer), homogenizing at 15,000 rpm
with a Polytron homogenizer (Kinematica, Basel, Switzerland) for 1
min, and centrifuging at 1000  g for 10 min at 4°C. For separating
membrane and cytosolic fractions, supernatants were centrifuged fur-
ther at 100,000  g for 1 h at 4°C. Extracts of human cancellous bone
were prepared by shaking fragments of bone tissue, snap-frozen in
liquid nitrogen, at 2500 rpm for 2 min using a Mikro-Dismembranator
S homogenizer (B. Braun Biotech, Melsungen, Germany). The crushed
bone was resuspended in homogenization buffer and centrifuged as
above. Protein concentrations were determined using the BioRad Pro-
tein Assay kit (Hercules, CA), and 30 or 40 g of each was used for
PAGE.
Osteoclast Culture
CD14-positive monocytes were isolated from peripheral blood of
normal volunteers by magnetic bead sorting (Millenyi Biotec, Sunny-
vale, CA) according to the manufacturer’s protocol. For generating
osteoclasts, cells were cultured in -MEM supplemented with 10% FCS
(Invitrogen), human recombinant M-CSF (25 ng/ml; R&D Systems,
Abingdon, UK), and human recombinant soluble RANKL (50 ng/ml;
Insight Biotechnology, Wembley, UK) on Osteologic calcium phos-
phate–coated slides (BD Biosciences, Oxford, UK) for 7 d at 37°C in 5%
CO2. Cells then were either prepared for immunofluorescence analysis
by washing in PBS; fixing in 4% paraformaldehyde; permeabilizing
using 0.1% Triton X-100; and staining for a3, d2, and vitronectin recep-
tor (VNR) as described below or stained using Diffquik (Baxter, Mc-
Gaw Park, IL) to identify osteoclasts and resorption pits. Diffquik-
stained cells were visualized on a Nikon E800 microscope, and images
were captured using a Basler camera.
Immunolocalization
Samples of normal human kidney were obtained from the unaffected
portions of nephrectomy specimens removed for renal tumors. Samples
were snap-frozen in Tissue-Tek O.C.T Compound (Sakura FineTek
Europe, Zoeterwoude, The Netherlands), using isopentane cooled over
liquid nitrogen. Serial 7-m frozen cryostat-cut sections were placed on
poly-l-lysine-coated (BDH) (Dagerham, UK) slides and stored at
80°C until use.
Neonatal ribs were collected post mortem from infants who were
born at full term with no evidence of growth retardation or skeletal
abnormalities. Ribs were immediately placed on ice and then embed-
ded in 5% polyvinyl alcohol (Sigma) and snap-frozen in liquid nitrogen.
Serial 9-m frozen sections were cryostat-cut and picked off onto 2%
3-aminopropyltriethoxysilane–coated (Sigma) slides, air dried for 15
min, and stored at 80°C until use.
Sections were permeabilized with 100% methanol for 5 min at20°C
and washed twice with PBST (1 PBS, 0.01% Tween 20). Sections were
incubated in 0.5% BSA/PBST for 15 min at room temperature, before
primary antibody was applied overnight at 4°C. Primary antibodies
were diluted in 0.5% BSA/PBST as follows: Guinea pig anti-human d2
(SK20) or preimmune serum 1:100; affinity-purified SK20 1:3; rabbit
anti-human a3 1:1000 (gift of Jan Mattsson, AstraZeneca, Mo¨lndal,
Sweden); rabbit anti-human a4 (RA2922 [14]) 1:3000; rabbit anti-rat/
mouse aquaporin-2 1:100 (Chemicon International, Temecula, CA); rab-
bit anti-OKP cell (opossum) megalin 1:500 (gift of Daniel Biemesderfer,
Yale University); and mouse monoclonal 23C6 anti-human VNR 1:5
(gift of Mike Horton, University College London). Sections were
washed three times with PBST before the following secondary antibod-
ies (Molecular Probes, Eugene, OR) were applied at 1:250 dilution in
0.5% BSA/PBST for 1 h at room temperature: Goat anti-guinea pig
Alexa 488, goat anti-rabbit Texas Red, and goat anti-mouse Alexa 568.
After sections were washed three times with PBST, they were mounted
with VECTASHIELD Mounting Medium with DAPI (Vector Laborato-
ries, Burlingame, CA) and viewed using either a Zeiss Axiovert 200M
fluorescence microscope and Improvision Openlab Volume Deconvo-
lution software or a Zeiss LSM510 META confocal microscope.
Nephrogenesis Studies
Samples from human fetal kidneys, ranging from 12 to 25 wk of
gestation, neonatal kidney at 4 mo, and adult kidney were obtained
from the International Institute for Advancement of Medicine (Phila-
delphia, PA) and the Anatomic Gift Foundation (Woodbine, GA).
Mouse kidney samples were obtained from CD-1 mice (Iffa Credo,
Brussels, Belgium). Pregnant mice were killed by cervical dislocation.
Embryos were removed and microdissected to isolate kidneys. Em-
bryos from four different litters (average 12 embryos/litter) were col-
lected every day from embryonic day 13.5 (E13.5) until day 5 after birth
(newborn). Comparative studies were performed with four adult male
kidneys.
Mouse kidney samples were homogenized in TRIzol, and total RNA
was extracted and reverse-transcribed as described above. For semi-
quantitative reverse transcription–PCR (RT-PCR), cDNA preparations
were amplified using the following primers: Atp6v0d2, CTTGAGTTT-
GAGGCCGACAG and TTGAGCTAACAACCGCAACC; Atp6v0d1,
GCCAGCTTCCTGGACTTCAT and ACAGCCTCCATCTGCTCAAA;
Atp6v1e1, GGCGCTCAGCGATGCAGATGT and CAAGGCGACCTT-
TCTCAATG; and Atp6v0a3, TGCTCATGGGTCTGTTCTCC and CAT-
GGAGTGCTGGGACAGAT, which give products of 138, 143, 134, and
149 bp, respectively. A 177-bp fragment of G3PDH was amplified in
parallel using primers TGCACCACCAACTGCTTAGC and GGATG-
CAGGGATGATGTTCT. PCR conditions were 94°C for 5 min followed
by 35 (d2 subunit), 32 (d1 subunit), 33 (E1 subunit), 35 (a3 subunit), and
30 (G3PDH) cycles of 30 s at 95°C, 30 s at 61°C, and 1 min at 72°C.
Negative controls included non–reverse-transcribed RNA samples and
sterile water.
Real-time PCR analyses (iCycler iQ System; BioRad) were performed
in duplicate using the primers shown above and iQ SYBR Green
Supermix as described previously (17). PCR mixtures contained 10 nM
fluorescein for initial well-to-well fluorescence normalization. PCR con-
ditions were as follows: 94°C for 3 min followed by 40 (30 s at 95°C,
30 s at 61°C, and 1 min at 72°C). The melting temperature of each PCR
product was established by recording SYBR Green fluorescence in-
crease upon slowly renaturing DNA at the end of PCR. For each assay,
standard curves were prepared by serial four-fold dilutions of mouse
adult kidney cDNA. Relative mRNA expression of the d2, d1, E1, and a3
subunits was investigated in four adult male kidneys, after normalization
to G3PDH: Ratio  2Ct (G3PDHTarget Gene). At each embryonic stage,
mRNA levels of the different subunits were adjusted to the G3PDH
mRNA level, and relative changes in mRNA levels during ontogeny
were determined by comparison to the adult level (taken as 100%)




Kidney membrane extracts were prepared for Western blot analysis
as described previously (19). Immunoblotting was carried out by stan-
dard methods, using a mouse mAb against the bovine E1 subunit (gift
of Stephen Gluck, Gainesville, FL) at a 1:100 dilution and guinea pig
anti-human d2 (SK20) at a 1:1000 dilution. Normalization for -actin
was obtained after stripping the blots and reprobing with a mouse
monoclonal anti–-actin antibody (Sigma). All immunoblots were per-
formed at least in duplicate.
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Screening of ARO Kindreds
With appropriate local ethical approval, genomic DNA from the
affected index cases of 25 ARO kindreds and one with coexistent
osteopetrosis and RTA was prepared from whole blood by standard
procedures (20). All exons of the ATP6V0D2 gene were individually
amplified by PCR, using primers designed from intronic sequences
flanking each exon. PCR products were sequenced using BigDye Ter-
minator v3.1 Cycle Sequencing (Applied Biosystems, Foster City, CA).
Results
Expression Profile of the Murine d2 Subunit
We first used RT-PCR analysis to assess the gene expression
profiles of the d1 and d2 subunit isoforms in a panel of 10
mouse tissues (Figure 2A). This demonstrated that the d1 iso-
form is ubiquitously expressed, whereas d2 is predominantly
expressed in kidney, bone, and lung. The d2 isoform is also
expressed at apparently lower levels in thymus, skeletal mus-
cle, heart, and liver, although it must be noted that the assay is
not quantitative. These findings are broadly in agreement with
those seen previously in human, where d2 was expressed
chiefly in kidney and osteoclasts (10).
Mouse Nephron Segment–Specific RT-PCR
To investigate the renal distribution of d2, we used RT-PCR
to examine d2 expression in defined tubule segments prepared
from mouse kidney as described previously (21). As shown in
Figure 2B, d2 mRNA is present in proximal tubule, cortical
collecting duct, outer medullary collecting duct, inner medul-
lary collecting duct, and papilla. It does not seem to be ex-
pressed in the thin loop of Henle or the distal convoluted
tubule.
Antibody SK20 Specifically Recognizes the d2 Subunit
We wished to confirm the localization of d2 in kidney at the
protein level and also look at the distribution of this subunit in
bone. We therefore raised a polyclonal antibody (SK20) in
guinea pig, directed against two regions of the human d2
protein: An internal peptide of 13 residues and one correspond-
ing to the C terminal 17 residues. We first confirmed specificity
by ELISA using SK20 with and without separate affinity puri-
fication against the immunizing peptides. Immunoblotting ex-
tracts from kidney and brain showed that SK20 recognizes a
protein of approximately 40 kD, corresponding to the predicted
size of d2, in human kidney membrane extract but not kidney
cytosol (Figure 3A). No d2 signal was seen using preimmune
serum from the same animal (data not shown). Both crude and
affinity-purified SK20 also cross-reacted with d2 in mouse and
rat kidney membrane (Figure 3B). No band corresponding to d2
was seen in mouse brain membrane extract (data not shown).
This is consistent with the RT-PCR analysis and, importantly,
indicates that SK20 does not cross-react with the ubiquitously
expressed d1 isoform.
Immunolocalization of d2 in Human Kidney
SK20 was used to localize d2 in unfixed frozen human kidney
sections. High-intensity d2 staining was seen at the apical sur-
face of intercalated cells in both cortical and medullary collect-
ing ducts, with some appearing intracellularly. This appearance
of d2 co-localized completely with a4 staining (Figure 4, A and
B), confirming the cell type. No d2 staining was seen in cells
that were positive either for the principal cell marker aqua-
porin-2 (Figure 4D) or for the proximal tubule marker megalin
(Figure 4E). Specificity of the d2 staining was confirmed by its
absence when preimmune serum from the same animal was
substituted (Figure 4C).
Figure 2. Reverse transcription–PCR (RT-PCR) amplification of
d1 and d2 subunit mRNA from mouse tissues. (A) PCR ampli-
fication of cDNA from 10 mouse tissues was performed using
gene-specific primers. Atp6v0d1 (535-bp product) is expressed
in all tissues. In contrast, Atp6v0d2 (532 bp) is expressed chiefly
in kidney, bone, and lung. -Actin–specific primers generated a
540-bp product in all tissues, confirming successful reverse
transcription. Water replaced cDNA as a negative control. Size
markers (M) are in increments of 100 bp; arrowheads indicate
the 500-bp band. (B) PCR amplification of Atp6v0d2 was per-
formed using cDNA prepared from defined segments of the
mouse nephron: Total kidney (lane 1), proximal tubule S1 with
glomerulus (lane 2), proximal tubule S1-S3 (lane 3), thin loop of
Henle (lane 4), distal tubule (lane 5), cortical collecting duct
(lane 6), outer medullary collecting duct (lane 7), inner medul-
lary collecting duct (lane 8), papilla (lane 9), and negative
control (lane 10). Atp6v0d2 mRNA (532-bp product) is present
in all of the segments studied except the thin limb of Henle’s
loop and distal tubule. Glyceraldehyde-3-phosphate dehydro-
genase (G3PDH)-specific primers generated a 452-bp product
in all tubule segments, confirming successful reverse transcrip-
tion. Size markers (M) are in increments of 100 bp; arrowheads
indicate the 500-bp band.
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Immunolocalization of d2 in Cultured Human Osteoclasts
and Human Neonatal Rib Bone
We studied d2 expression in bone both in vitro and ex vivo.
Primary osteoclasts that were cultured on a synthetic resorb-
able substrate were used to demonstrate sites of localization of
d2, the H-ATPase a3 subunit, and the VNR (integrin V3), a
marker of osteoclast activity. Areas of lysis of the substrate
were always associated with large multinucleated cells, indi-
cating active resorption (Figure 5A). By confocal microscopy,
these large cells were identified as osteoclasts, first by their
intense staining for VNR and second by their multinuclearity
seen with DAPI staining (Figure 5B). VNR was widely localized
in the plasma membrane, again indicative of resorptive activity.
There was less VNR staining within a basal area, within which,
in these same cells, a3 and d2 co-localized, adjacent to the
substrate (Figure 5C). a3 is known to be present at the ruffled
border of osteoclasts and in late endosomes and lysosomes (22).
The in vivo localization of d2 in unfixed frozen human neo-
natal rib bone sections was also studied using SK20. Staining
was confined to osteoclasts, as confirmed by positive staining of
VNR (Figure 5D). d2 signal fully co-localized with staining for
a3 in these cells (Figure 5E). No specific staining was seen when
preimmune serum from the same animal was substituted (Fig-
ure 5F).
Thus, d2 is co-expressed with the a4 subunit in kidney and
the a3 subunit in bone. However, Northern blot and RT-PCR
(23–25) have demonstrated a3 mRNA in human and mouse
kidney, and immunoprecipitation data have suggested that a3
protein is expressed in mouse kidney (26). We therefore sought
to determine whether d2 is also co-expressed with the a3 sub-
unit in human renal tissue, but on no occasion did the anti-a3
antibody show a staining pattern in human kidney sections.
This does not necessarily exclude low levels of a3 protein
expression in kidney but suggests that it may be present only at
levels that are undetectable using this antibody. Conversely, a4
immunofluorescence was not detectable in bone sections (data
not shown), confirming our previous negative RT-PCR findings
from both mouse and human (8 and Smith et al., unpublished
data).
Comparative Quantification of d2 mRNA in Adult and
Developing Mouse Kidney
We conducted real-time RT-PCR studies to establish the rel-
ative expression of d2 with respect to several other H-ATPase
subunits (d1, E1, and a3) both during mouse nephrogenesis and
in adult mouse kidney. As might be expected from its limited
distribution pattern, these studies showed that in mature kid-
ney, the d2 subunit mRNA was approximately 20-fold less
prevalent than was message for the E1 subunit (Figure 6, A and
B) and approximately 10-fold less abundant than d1 mRNA,
both of which are ubiquitously expressed. a3 subunit mRNA
was also less well expressed, by approximately the same frac-
tions.
In the developing kidney, semiquantitative (Figure 6C) and
real-time (Figure 6D) PCR analyses showed detectable d2
mRNA expression at E15.5 (approximately 10% of the adult
level), with a progressive increase during late ontogeny (E17.5;
approximately 45%) to reach the adult level at birth. By con-
trast, the ubiquitous d1 and E1 subunits were characterized by
earlier (E13.5) expression, but whereas E1 levels seemed stable
(approximately 50% of the adult level) throughout nephrogen-
esis followed by a significant increase at birth, as previously
observed (17), the d1 isoform gradually decreased during late
ontogeny before a neo-induction at birth. Although overall
levels of a3 were low in the adult kidney (Figure 6B), its
ontogeny pattern was characterized by an early and stable
expression at a relatively higher level (approximately 150% of
the adult level), with no significant change until after birth.
We also investigated the ontogeny pattern of d2 at the pro-
tein level. Immunoblotting (Figure 6E) confirmed the later de-
tection of d2 expression at E15.5 compared with E1, but in
contrast to the mRNA data, expression of E1 was seen to
increase gradually from E16.5 until birth. However, there was
only a negligible increase in d2 protein expression levels during
late ontogeny, which contrasts with the semiquantitative and
real-time PCR analyses. Of note, the d2 immunoreactive pattern
was seen as a doublet in the fetal and newborn samples,
whereas only the lower molecular weight band was present in
the adult sample.
Expression of the d2 Subunit during Human Nephrogenesis
The expression of the d2 subunit of the H-ATPase during
human nephrogenesis was also investigated using immuno-
blotting (Figure 6F). This subunit was detected from 12 gesta-
tional weeks and showed stable expression throughout kidney
organogenesis. As in mouse, d2 was detected in fetal samples
as a doublet, with increasing prominence of the larger band,
which was noted to persist in infancy, whereas only a single
band was observed in adult kidney, corresponding to the lower
molecular weight band as in mouse. The significance of this
doublet and the apparent switch in size are unclear at present.
Figure 3. Western blot analysis of d2 expression in kidney
extracts. (A) immunoblotting of human kidney cytosol (lane 1)
and human kidney membrane (lane 2). The guinea pig poly-
clonal antibody SK20 recognizes a protein of approximately 40
kD (indicated by the arrow), corresponding to the predicted
size of d2, in human kidney membrane extract but not in
kidney cytosol. (B) Immunoblotting, using affinity-purified
SK20, of human kidney membrane (lane 1), rat kidney mem-
brane (lane 2), and mouse kidney membrane (lane 3). SK20
cross-reacts with d2 in rat and mouse kidney membrane (indi-
cated by the arrow).
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Screening ARO Patients
Having found co-localization of d2 and a3 in osteoclasts, we
proceeded to assess the candidacy of the ATP6V0D2 gene encod-
ing the d2 subunit as a causative gene of autosomal recessive
osteopetrosis. We obtained genomic DNA from a 39-yr-old white
woman who had osteopetrosis accompanied by a urine acidifica-
tion defect, hypokalemia, and nephrocalcinosis and in whom nor
mal carbonic anhydrase II levels have been found. Direct sequenc-
ing of coding exons and exon-intron boundaries of ATP6V0D2
revealed no departures from wild-type sequence.
We also screened the gene in a cohort of 25 patients from 23
kindreds that either do not have potential disease-associated muta-
tions in genes that are known to cause ARO, namely TCIRG1,
CLCN7, and OSTM1, which encode the H-ATPase a3 subunit,
Figure 4. Immunolocalization of d2 in human kidney. SK20 was used to localize d2 in 7 m unfixed frozen human kidney sections.
Cortex (A) and medulla (B) incubated with SK20 (green) and the anti-a4 antibody RA2922 (red) reveal high-intensity d2 staining,
co-localizing with a4 staining (yellow), at the apical surface of intercalated cells in the collecting duct (examples indicated by arrows).
The specificity of d2 staining was confirmed by its absence when preimmune serum from the same animal was substituted (medulla;
C). Confirmation of the collecting duct intercalated cell localization of d2 was provided by the absence of co-localization with either the
principal cell marker aquaporin-2 (AQP-2; medulla; D) or the proximal tubule marker megalin (cortex; E). All scale bars  25 m.
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ClC-7 chloride channel, and grey-lethal protein, respectively (13 pa-
tients), or inwhomonly onedisease-causing allele has been identified
(12 patients). The affected subjects allmet the clinical and biochemical
criteria for thedisease. RTAwas absent in this group. Twenty of these
patients have been previously reported (16,27,28). No potential dis-
ease-causing sequence alterationswere found. This sequence analysis
did identify a heterozygous single-nucleotide polymorphism (SNP),
814G3A, in exon 6 in one patient, which results in a missense
alteration (G272R). As this SNP was also found heterozygously in
both unaffected parents, it cannot be disease causing in isolation in
the heterozygous state. We subsequently found that this SNP has
recently been entered into theNCBI dbSNPdatabase. In addition,we
identified twonovel intronic SNP (IVS4–12C3Tand IVS542C3T)
that were common, each being present in five patients.
Figure 5. Immunolocalization of d2 in human cultured osteoclasts and neonatal rib bone. (A through C) Primary human osteoclasts
cultured on a synthetic resorbable substrate. (A) Light microscopy reveals two large multinucleated osteoclasts (arrowheads) and
associated areas of substrate lysis (*). (B and C) Merged confocal images of single osteoclasts stained for d2 (green) and one of two
osteoclast markers (red): Vitronectin receptor (VNR; B) or the H-ATPase a3 subunit (C). Nuclei were stained using DAPI (blue).
(B) VNR staining localizes to the plasma membrane, and d2 staining is seen intracellularly and in the ruffled border region,
adjacent to the substrate. (C) d2 staining co-localizes with a3 (yellow). White arrowheads indicate planes of cross section. (D
through F) 9-m human frozen neonatal rib bone sections, stained for d2 and either VNR (D) or a3 (E) as above. DAPI staining
demonstrates the presence of one multinucleated osteoclast per panel. As seen with cultured osteoclasts, d2 and a3 co-localize (E),
with VNR staining present mainly at the cell surface (D). Specificity of d2 staining was confirmed by its absence when preimmune
serum was substituted (F). All scale bars  50 m.
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Figure 6. Comparative ontogeny of the d2, d1, E1, and a3 subunits during mouse and human nephrogenesis. (A) Representative
tracings of G3PDH, a3, d1, d2, and E1 mRNA amplification by real-time RT-PCR in adult mouse kidney. (B) Comparative mRNA
quantification by real-time RT-PCR of a3, d1, d2, and E1 subunits in adult mouse kidney (n  4). After normalization to G3PDH,
d2 and a3 were each approximately 20- and 10-fold less abundant than E1 and d1, respectively (one-way ANOVA, P  0.001). (C)
Representative semiquantitative PCR analysis of the expression of d2, d1, a3, E1, and G3PDH during embryogenesis (E13.5, E15.5,
E17.5) and in neonatal and adult mouse kidneys. Negative controls with water (W) and non–reverse-transcribed product (N) are
shown. The size of the PCR products is shown in bp. (D) Quantitative real-time RT-PCR of d2, d1, a3, and E1 mRNA expression
during mouse nephrogenesis. mRNA levels were adjusted to G3PDH for each stage. The relative changes in expression during
ontogeny were determined by comparison with the adult mRNA level taken as 100%. d2 mRNA is first detected at E15.5
(approximately 10% of the adult value), with a progressive increase during late ontogeny (E17.5; approximately 45%) to reach the
adult expression level at birth. By contrast, ontogeny of d1 is characterized by early expression followed by a slight decrease and
a neo-induction at birth, whereas E1 mRNA expression starts early during nephrogenesis and remains stable (approximately 50%
of the adult value) throughout ontogeny, with a subsequent upregulation at birth. a3 shows an early (E13.5) and stable fetal
expression at higher levels (approximately 150% of the adult level), without significant changes until after the neonatal period. (E)
Representative immunoblots for d2, E1, and -actin in extracts from embryonic (E13.5 to E18.5), neonatal, and adult mouse
kidneys. Thirty micrograms of protein was loaded in each lane, and blots were probed with antibodies against d2, E1, and, after
stripping, -actin. The d2 subunit is detected from E15.5, with a slight increase during late ontogeny. In embryonic samples, d2
appears as a doublet, which is not found in mature kidneys. The E1 subunit is detected early during nephrogenesis and gradually
increases from E16.5 until birth. (F) Representative immunoblots of d2 and -actin in human fetal (from 12 to 25 wk gestation
[GW]), 4-mo-old, and adult kidneys. The d2 subunit was detected early during human nephrogenesis at 12 wk gestation, again
as a doublet. d2 expression was present throughout development, with a postnatal maturation as in the mouse.
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Discussion
Our investigations of the H-ATPase d2 subunit confirm its
limited tissue expression in mouse as well as in human. Nota-
bly, we demonstrate here that this subunit coexists with differ-
ent a-subunit isoforms in the different specialized proton
pumps that occur at the plasma membrane in distinct cells in
kidney and in bone. This supports the idea that the existence of
H-ATPase subunit isoforms is important for allowing the
development of diverse and often specialized functions of pro-
ton pumps. Apart from G2, which is brain specific, and the
a-subunit, which had already been shown to exist in a paralo-
gous form in bone, the variance of subunit isoforms in different
tissues has to date been limited to epithelia, whether in kidney,
inner ear, lung, or male genital tissue. The d2 and a3 subunits
are now revealed to co-localize in osteoclasts, which are of very
different embryologic origin.
The polyclonal SK20 antiserum used here specifically recog-
nizes d2 in human, mouse, and rat kidney, and it is detectable
only in the membrane fraction. Our immunolocalization results
in human kidney showed that d2 is present at high density at
the apical pole of intercalated cells in both cortical and medul-
lary collecting ducts, co-localizing with a4, but it is not seen in
the proximal tubule. This distribution parallels previous find-
ings for other subunits, specifically B1 in both human and
rodent kidney, human a4, and the C2-b isoform in mouse
(6,14,26,29). In these cases, no significant signal was observed in
glomeruli or proximal and distal convoluted tubules. However,
there is some discrepancy with regard to a4, where proximal
staining was observed in mouse kidney (8), and it is also
reported in both human and mouse renal tissue subjected to
antigen retrieval techniques (21). This could be due to technical
differences in fixation and retrieval and/or species-specific ex-
pression patterns. Our d2 results also show a difference be-
tween protein and nephron segment RT-PCR expression pat-
terns, but the detection of d2 mRNA in proximal tubule by this
particularly sensitive technique does not necessarily suggest
the presence of d2 protein.
The murine d2 isoform can be co-immunoprecipitated from
renal tissue with the B1 but not the ubiquitously expressed B2
subunit (26). Because under normal conditions it is the B1
rather than the B2 subunit that participates in the surface-
destined luminal and basolateral proton pumps of - and -in-
tercalated cells, respectively (6), this suggests that d2 is present
only in these particular specialized proton pumps of the kid-
ney, which in rodents also contain a4, C2-b, and G3 (7,8,26).
In contrast, further immunoprecipitation studies using
mouse kidney have revealed an association between a3 and the
B2 but not the B1 subunit (26). Because there is evidence to
suggest that a3 mRNA is detectable in kidney in human as well
as in mouse (24), we were interested to know whether a3
protein could be observed in the human kidney as well. In the
event, a3 could not be seen. This suggests either a species
difference or that if a3 is translated in the human kidney, it is
present only at levels that are too low to permit detection.
In human bone, we observed d2 expression only in oste-
oclasts. These cells are more prevalent in developing bone than
in adult cancellous bone, where they represent at most 1% of
the cells. This explains why the signal was too weak to be
visualized when SK20 was used in immunoblots of adult bone
extracts (data not shown).
The presence of d2 together with a3 at the ruffled membrane
and within osteoclasts may make either of these subunits at-
tractive drug targets for the treatment of osteoporosis, but in
the case of d2, this will inevitably depend on the consequences
for the kidney as well. In principle, there is great potential for
using H-ATPase inhibitors as antiresorptive therapeutics,
with the caveat that compounds directed at subunits with
widespread expression patterns are unlikely to be useful—such
as the pharmacologically active antagonist bafilomycin used in
in vitro studies to inhibit proton pump function. Instead, the
possibility of specifically targeting the osteoclast membrane
H-ATPase is much more attractive, as long as any therapeutic
agent could be delivered efficiently to the desired site of action.
Indeed, a recent publication described a compound that can
discriminate between osteoclast vacuolar ATPase and lysoso-
mal vacuolar ATPase (30).
As with the a4 subunit (17), we have found that d2 subunit
expression differs temporally from the ubiquitously expressed
d1 and E1 subunits during nephrogenesis in that it first appears
later. This may well represent differences in the rate of matu-
ration of different segments of the developing nephron, in that
even at birth, collecting duct morphology and function are still
immature. Similarly, a postnatal increase in mRNA and protein
for the B1 and a4 subunits, both of which are important for
collecting duct function, was reported recently (31).
We also observed a d2 doublet in fetal samples. This might be
due to differential protein processing, for example by glycosyl-
ation or phosphorylation. Another possibility is that of alterna-
tive mRNA splicing, but we have observed only a single PCR
product when amplifying from various cDNA.
Given the specificity of d2 expression, we regarded it as a
good candidate gene for inherited osteopetrosis. We reasoned
that the likeliest phenotype would include both bone thicken-
ing and a urine acidification defect, as is seen in those with CA2
mutations (32), but also screened ARO patients who harbor one
or no mutations in the known ARO genes. We have not found
any disease-causing mutations in the patients who are available
to us, whether with or without accompanying RTA. In view of
the uncertainty about renal a3 expression in the human kidney,
it is notable that no renal phenotype is reported in recessive
osteopetrosis caused by ATP6V0A3 mutations, although it is
unlikely that this has been systematically sought.
The d subunit is classified as a component of the V0 domain
through protein–protein interactions rather than by integration
into the membrane itself and is proposed to be present at the
cytoplasmic side of the membrane. Its precise contribution to
H-ATPase function remains unclear, although Forgac et al.
(33) suggested that the d subunit may play a role in the cou-
pling of ATP hydrolysis to proton transport. Recently, the
crystallization of Thermus thermophilus subunit C, which is ho-
mologous to the eukaryotic d subunit, was reported (34). Solu-
tion of the crystal structure and its superposition onto the
low-resolution electron micrograph structure of the holoen-
zyme, using data from cross-linking experiments, suggest that
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this subunit serves as a socket to attach V1 central stalk subunits
onto the phospholipid ring of the V0 domain, which would
couple the two domains, in agreement with Forgac’s model.
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